Probiotic Intervention for Stress and Cognition

Sponsor
Probi AB (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04931082
Collaborator
(none)
132
1
2
12.8
10.3

Study Details

Study Description

Brief Summary

The effect of probiotics on stress and cognitive function in healthy adults with moderate stress

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Probiotics
  • Dietary Supplement: Placebo
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
132 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Randomized, Double-blinded, Placebo-controlled, Parallel Clinical Trial of a Probiotic on Stress and Cognitive Function in Healthy Adults
Actual Study Start Date :
Jul 7, 2021
Actual Primary Completion Date :
Mar 25, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Probiotics

One capsule per day for 12 weeks

Dietary Supplement: Probiotics
Capsule

Placebo Comparator: Placebo

One capsule per day for 12 weeks

Dietary Supplement: Placebo
Capsule

Outcome Measures

Primary Outcome Measures

  1. Determine whether intake of probiotics reduce perceived stress [12 weeks]

    Perceived stress will be evaluated with Cohen's Perceived Stress Scale (PSS) (min 0, max 40)

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Willing to participate in the study and comply with its procedures.

  • Be able to give written informed consent.

  • Be between 21 and 50 years.

  • Have moderate stress, as measured on Cohen's Perceived Stress Scale (PSS).

  • Are not suffering from depression or anxiety, confirmed by a Hospital Anxiety and Depression Scale (HADS) score.

  • Are not regularly consuming probiotics for at least 4 weeks prior to the Screening Visit.

  • Is in general good health, as determined by the investigator.

Exclusion Criteria:
  • Current diagnosis of currently active irritable bowel syndrome (IBS), according to Rome IV criteria.

  • Chronic intestinal disease, immunodeficiency disorder or immunosuppressive treatment.

  • Known gluten intolerance, lactose intolerance, milk protein allergy.

  • Intake of antibiotics within four weeks prior to the Screening Visit.

  • Hypersensitivity to any of the ingredients in the Investigational Product (IP).

  • Previous (within 5 years) or ongoing psychiatric illness.

  • Consumption of systemic psychotropics, rheumatoid drugs, steroid drugs or creams containing cortisone.

  • Regular consumption of asthma medications.

  • History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk if participating in the study, or influence the results or the participant´s ability to participate in the study.

  • Investigator considers the participant unlikely to comply with study procedures, restrictions, and requirements.

  • Any disease, that by the investigator's judgement, could interfere with the intestinal barrier function.

  • Participation in other clinical trials involving Investigational Product consumption in the last month.

  • Desire and/or plans on changing current diet and/or exercise regime during the participation of this trial.

  • Participants who are pregnant, breastfeeding, or wish to become pregnant during the study.

  • Participants currently of childbearing potential, but not using an effective method of contraception.

  • Have a malignant disease or any concomitant end-stage organ disease, which, in the Investigator's judgment, contraindicates participation in the study.

  • Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial.

  • Taking any supplements or vitamins notably known to affect cognitive function. Vitamin D and calcium supplements permitted if on a stable dose for the previous 3 months.

  • History of heavy caffeinated beverage consumption (>400 mg caffeine/day) within past 2 weeks prior to the Screening Visit.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Atlantia Food Clinical Trials Cork Ireland

Sponsors and Collaborators

  • Probi AB

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Probi AB
ClinicalTrials.gov Identifier:
NCT04931082
Other Study ID Numbers:
  • AFCRO-136
First Posted:
Jun 18, 2021
Last Update Posted:
Apr 20, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Probi AB

Study Results

No Results Posted as of Apr 20, 2022